Focal palmoplantar keratoderma with epidermolytic degeneration

Oiso, Naoki; Kawara, Shigeru; Kawada, Akira

doi:10.1111/j.1468-3083.2008.02857.x

Cited by 1 publication

(2 citation statements)

References 6 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pimecrolimus, a topical calcineurin inhibitor that blocks T-cell activation and cytokine production, has been used effectively in combination with dutasteride [3]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperpigmentation following Treatment of Frontal Fibrosing Alopecia

et al. 2013

View full text Add to dashboard Cite

Introduction: Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the most effective therapy. Side effects associated with dutasteride are erectile dysfunction as well as breast tenderness and enlargement, while pimecrolimus produces a burning sensation. Case Report: We present a 57-year-old postmenopausal female with a 3-year history of a scarring alopecic plaque in her frontotemporal region. Biopsy confirmed the diagnosis of FFA, and she was started on dutasteride 0.5 mg p.o. q.d., and later, topical pimecrolimus 1% b.i.d. was added. Eight months after initiating treatment, she showed hyperpigmentation on her metacarpophalangeal and interphalangeal joints, as well as on the cheeks and on the chin; dutasteride and pimecrolimus were discontinued. After 5 months of follow-up, her hyperpigmentation improved by 80% only by using photoprotection. Conclusion: Because of the variable clinical course of FFA, treatment is focused on halting its progression. Several therapeutic agents have been evaluated and the combination of dutasteride and pimecrolimus has shown a high response rate. There is no reported evidence of hyperpigmentation associated with this combination.

show abstract

“…Pimecrolimus, a topical calcineurin inhibitor that blocks T-cell activation and cytokine production, has been used effectively in combination with dutasteride [3]. …”

Section: Discussionmentioning

confidence: 99%

“…Currently, there is no treatment of choice and because of the scarring nature, the aim is to stop progression. Studies have shown that the combination of dutasteride and pimecrolimus is by far the most effective therapy for this condition, and even hair regrowth has been reported [2, 3]. …”

Section: Introductionmentioning

confidence: 99%